Compare Stocks: SION, APGE, IMVT, and PCVX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$134.68 -0.1%	$119.35	$34.40 ▼ $134.88	$8.33B	0.35	1.67 million shs	217,432 shs
IMVT Immunovant	$39.57 -1.0%	$37.23	$14.32 ▼ $41.23	$8.17B	0.77	1.54 million shs	113,284 shs
PCVX Vaxcyte	$58.63 +1.0%	$53.85	$29.50 ▼ $65.00	$8.47B	1.23	1.42 million shs	215,184 shs
SION Sionna Therapeutics	$4.18 -91.8%	$42.35	$4.05 ▼ $54.97	$189.61M	1.32	509,741 shs	18.02 million shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	0.00%	+0.56%	+0.89%	+59.39%	+281.01%
IMVT Immunovant	0.00%	+3.44%	+0.60%	+37.47%	+158.41%
PCVX Vaxcyte	0.00%	+7.38%	-0.24%	+7.56%	+94.21%
SION Sionna Therapeutics	0.00%	+8.30%	+12.70%	+11.08%	+188.85%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$134.68 -0.1%	$119.35	$34.40 ▼ $134.88	$8.33B	0.35	1.67 million shs	217,432 shs
IMVT Immunovant	$39.57 -1.0%	$37.23	$14.32 ▼ $41.23	$8.17B	0.77	1.54 million shs	113,284 shs
PCVX Vaxcyte	$58.63 +1.0%	$53.85	$29.50 ▼ $65.00	$8.47B	1.23	1.42 million shs	215,184 shs
SION Sionna Therapeutics	$4.18 -91.8%	$42.35	$4.05 ▼ $54.97	$189.61M	1.32	509,741 shs	18.02 million shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	0.00%	+0.56%	+0.89%	+59.39%	+281.01%
IMVT Immunovant	0.00%	+3.44%	+0.60%	+37.47%	+158.41%
PCVX Vaxcyte	0.00%	+7.38%	-0.24%	+7.56%	+94.21%
SION Sionna Therapeutics	0.00%	+8.30%	+12.70%	+11.08%	+188.85%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APGE Apogee Therapeutics	2.24	Hold	$121.25	-10.08% Downside
IMVT Immunovant	2.50	Moderate Buy	$44.00	10.14% Upside
PCVX Vaxcyte	2.38	Hold	$86.00	48.10% Upside
SION Sionna Therapeutics	2.85	Moderate Buy	$55.00	7.76% Upside

Current Analyst Ratings Breakdown

Latest SION, APGE, IMVT, and PCVX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2026	SION Sionna Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$50.00 ➝ $60.00
8/6/2026	SION Sionna Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$59.00
8/5/2026	SION Sionna Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/4/2026	IMVT Immunovant	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$47.00 ➝ $50.00
7/29/2026	IMVT Immunovant	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
7/17/2026	APGE Apogee Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/14/2026	PCVX Vaxcyte	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/6/2026	IMVT Immunovant	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/6/2026	PCVX Vaxcyte	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/30/2026	IMVT Immunovant	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$57.00 ➝ $61.00
6/24/2026	APGE Apogee Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform ➝ Neutral	$110.00 ➝ $135.00

(Data available from 8/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	$13.23 per share	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	$4.19 per share	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	$20.51 per share	N/A
SION Sionna Therapeutics	N/A	N/A	N/A	N/A	$6.88 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APGE Apogee Therapeutics	-$255.84M	-$4.33	N/A	N/A	N/A	N/A	-32.64%	-31.25%	8/10/2026 (Estimated)
IMVT Immunovant	-$505.61M	-$2.82	N/A	N/A	N/A	N/A	-69.59%	-62.49%	N/A
PCVX Vaxcyte	-$766.63M	-$7.63	N/A	N/A	N/A	N/A	-37.56%	-33.62%	N/A
SION Sionna Therapeutics	-$75.27M	-$2.18	N/A	N/A	N/A	N/A	-32.94%	-31.08%	N/A

Latest SION, APGE, IMVT, and PCVX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	APGE Apogee Therapeutics	-$1.07	-$2.07	-$1.00	-$2.0650	$10.00 million	N/A
8/6/2026	Q1 2027	IMVT Immunovant	-$0.6289	-$0.75	-$0.1211	-$0.75	$7.10 million	$7.10 million
8/6/2026	Q2 2026	SION Sionna Therapeutics	-$0.64	-$0.66	-$0.02	-$0.66	N/A	N/A
8/5/2026	Q2 2026	PCVX Vaxcyte	-$2.06	-$1.97	+$0.09	-$1.97	$12.50 million	N/A
5/20/2026	Q4 2026	IMVT Immunovant	-$0.60	-$0.73	-$0.13	-$0.73	N/A	N/A
5/12/2026	Q1 2026	SION Sionna Therapeutics	-$0.52	-$0.60	-$0.08	-$0.60	N/A	N/A
5/11/2026	Q1 2026	APGE Apogee Therapeutics	-$1.0658	-$1.06	+$0.0058	-$1.06	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	N/A
SION Sionna Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APGE Apogee Therapeutics	N/A	32.59	32.59
IMVT Immunovant	N/A	7.27	7.27
PCVX Vaxcyte	N/A	5.72	5.72
SION Sionna Therapeutics	N/A	20.05	20.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APGE Apogee Therapeutics	79.04%
IMVT Immunovant	47.08%
PCVX Vaxcyte	96.78%
SION Sionna Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
APGE Apogee Therapeutics	24.30%
IMVT Immunovant	1.90%
PCVX Vaxcyte	3.30%
SION Sionna Therapeutics	5.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APGE Apogee Therapeutics	91	61.88 million	46.84 million	Optionable
IMVT Immunovant	120	206.55 million	202.63 million	Optionable
PCVX Vaxcyte	160	144.40 million	139.63 million	Optionable
SION Sionna Therapeutics	35	45.21 million	42.91 million	N/A

SION, APGE, IMVT, and PCVX Headlines

Recent News About These Companies

Stifel Nicolaus Reaffirms "Hold" Rating for Sionna Therapeutics (NASDAQ:SION)

39 minutes ago | marketbeat.com

Sionna Therapeutics, Inc. (SION) Shares Plummet Following Clinical Trial Results - Johnson Fistel Investigates

1 hour ago | newsfilecorp.comN

Sionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate Update

1 hour ago | manilatimes.netM

Sionna’s experimental cystic fibrosis pill falls flat in mid-stage trial

1 hour ago | statnews.comS

Sionna scraps genetic disorder drug program after trial setback; shares tank

1 hour ago | msn.com

Sionna Reports Mixed Trial Results, Refocuses CF Pipeline

2 hours ago | tipranks.com

Sionna Therapeutics Reports Second Quarter 2026 Financial Results

August 6, 2026 | markets.businessinsider.com

Sionna Therapeutics Reports Second Quarter 2026 Results and Advances CF Clinical Programs Toward Summer Data Readouts

August 6, 2026 | quiverquant.comQ

Sionna Therapeutics (NASDAQ:SION) Reaches New 52-Week High - Should You Buy?

August 4, 2026 | marketbeat.com

Perceptive Advisors LLC Decreases Position in Sionna Therapeutics, Inc. $SION

August 2, 2026 | marketbeat.com

36,540 Shares in Sionna Therapeutics, Inc. $SION Purchased by Stempoint Capital LP

July 30, 2026 | marketbeat.com

Brokerages Set Sionna Therapeutics, Inc. (NASDAQ:SION) Target Price at $53.22

July 30, 2026 | americanbankingnews.com

Sionna Therapeutics, Inc. $SION Position Decreased by Orbimed Advisors LLC

July 27, 2026 | marketbeat.com

Sionna Therapeutics, Inc. (NASDAQ:SION) Given Consensus Recommendation of "Moderate Buy" by Analysts

July 25, 2026 | marketbeat.com

Sionna Therapeutics (NASDAQ:SION) Stock Price Down 4.5% - What's Next?

July 20, 2026 | marketbeat.com

Jennison Associates LLC Has $58.18 Million Holdings in Sionna Therapeutics, Inc. $SION

July 20, 2026 | marketbeat.com

Sionna Therapeutics (NASDAQ:SION) Hits New 12-Month High - Should You Buy?

July 18, 2026 | marketbeat.com

Sionna Therapeutics (NASDAQ:SION) Trading Up 5.3% - Time to Buy?

July 17, 2026 | marketbeat.com

Sionna Therapeutics

July 13, 2026 | fool.com

Candriam S.C.A. Buys New Position in Sionna Therapeutics, Inc. $SION

July 13, 2026 | marketbeat.com

Insider Selling: Sionna Therapeutics (NASDAQ:SION) Director Sells 85,918 Shares

July 10, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SION, APGE, IMVT, and PCVX Company Descriptions

Apogee Therapeutics NASDAQ:APGE

$134.68 -0.16 (-0.12%)

As of 10:44 AM Eastern

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Immunovant NASDAQ:IMVT

$39.56 -0.39 (-0.96%)

As of 10:43 AM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Vaxcyte NASDAQ:PCVX

$58.63 +0.56 (+0.97%)

As of 10:44 AM Eastern

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Sionna Therapeutics NASDAQ:SION

$4.18 -46.86 (-91.80%)

As of 10:44 AM Eastern

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients. Our goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide-binding domain 1 (“NBD1”). Despite having long been identified as a critical component for proper CFTR function, NBD1 has been considered “undruggable,” and none of the currently approved CF therapies directly stabilizes NBD1. Worldwide revenue for approved CFTR modulators was approximately $10 billion in 2023 and is expected to grow to $15 billion by 2029. Leveraging more than a decade of our co-founders’ research on NBD1, we are advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in the NBD1 domain. Approximately 90% of people with CF carry at least one copy of the F508del genetic mutation. We believe stabilizing NBD1 is central to unlocking dramatic improvements in clinical outcomes and quality of life for CF patients. We have employed biophysical, cell-based and virtual screening campaigns and extensive use of structural biology to guide the optimization of novel small molecule NBD1 stabilizers. We are conducting ongoing Phase 1 trials of our two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (“PK”) profile of single and multiple ascending doses in healthy subjects. These trials are randomized (3:1 active:placebo), doubled-blinded, placebo-controlled and are being conducted in Australia. As of January 14, 2025, five single ascending dose (“SAD”) cohorts and three multiple ascending dose (“MAD”) cohorts of SION-719 have been completed, with over 60 healthy subjects dosed, and six SAD cohorts and three MAD cohorts of SION-451 have been completed, with over 70 healthy subjects dosed. Both SION-719 and SION-451 have been generally well tolerated based on interim Phase 1 clinical data as of the data cutoff date of January 14, 2025. We have established target exposure levels for SION-719 and SION-451 to potentially provide clinically meaningful benefit, if administered as part of a dual combination or as an add-on to the current standard of care (“SOC”), based on our preclinical cystic fibrosis human bronchial epithelial (“CFHBE”) model. In these trials, we have achieved the target concentrations for SION-719 and SION-451 with single and multiple doses. We plan to continue enrolling healthy subjects in additional MAD cohorts. We are also developing a portfolio of complementary CFTR modulators designed to work synergistically with our NBD1 stabilizers to improve CFTR function, as seen in preclinical models. In July 2024, we in-licensed three clinical-stage compounds from AbbVie Global Enterprises Ltd. (“AbbVie”) to expand our portfolio of combination product opportunities, including galicaftor (SION-2222), which targets CFTR’s transmembrane domain 1 (“TMD1”), and has completed Phase 2 clinical trials. In addition, we recently completed a Phase 1 clinical trial evaluating SION-109, which targets CFTR’s intracellular loop 4 (“ICL4”) region. We plan to evaluate multiple NBD1 stabilizer candidates and complementary modulator candidates and select the most promising candidates to advance into later-stage development. Initially, we intend to evaluate the lead NBD1 stabilizer candidate in combination with the current standard of care, Trikafta, in a proof-of-concept trial. In parallel, we will determine the proprietary dual combination that we believe is optimal to advance into a later-stage clinical trial in CF patients. We were incorporated under the laws of the State of Delaware in August 2019 under the name Sling Therapeutics, Inc., and changed our name to Sionna Therapeutics, Inc. in July 2021. Our principal executive offices are located at 21 Hickory Drive, Suite 500, Waltham, MA. We have one subsidiary, Sionna Therapeutics Securities Corporation (f/k/a Sling Therapeutics Securities Corporation), formed in 2020 under the laws of the Commonwealth of Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SION, APGE, IMVT, and PCVX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SION, APGE, IMVT, and PCVX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SION, APGE, IMVT, and PCVX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SION, APGE, IMVT, and PCVX Company Descriptions

Apogee Therapeutics NASDAQ:APGE

Immunovant NASDAQ:IMVT

Vaxcyte NASDAQ:PCVX

Sionna Therapeutics NASDAQ:SION

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SION, APGE, IMVT, and PCVX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SION, APGE, IMVT, and PCVX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SION, APGE, IMVT, and PCVX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SION, APGE, IMVT, and PCVX Company Descriptions

Apogee Therapeutics NASDAQ:APGE

Immunovant NASDAQ:IMVT

Vaxcyte NASDAQ:PCVX

Sionna Therapeutics NASDAQ:SION

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools